Source:

Healio Coverage

December 28, 2020
1 min read
Save

Top in cardiology: Modified Mediterranean diet, premature coronary artery disease

Source:

Healio Coverage

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A recent randomized clinical trial showed how a modified Mediterranean diet provided additional cardiometabolic benefits besides those obtained with the conventional Mediterranean diet. It was the top story in cardiology last week.

Another top story discussed some of the consequences of premature coronary artery disease.

Mediterranean Diet
Source: Adobe Stock

Read these and more top stories in cardiology below:

Mediterranean diet modified with more plant-based foods may reduce CV risk

Decreased meat intake supplemented with a parallel increase in plant-based foods may amplify the beneficial cardiometabolic effects of the Mediterranean diet and reduce CV risk, according to a study published in Heart. Read more.

Premature coronary artery disease tied to frequent ischemic recurrences, premature death

Patients with premature coronary artery disease had frequent ischemic recurrences and a high proportion of modifiable CV risk factors, and often died young, researchers reported. Read more.

Cardiac arrest prevalence low 90 days after MI

Researchers observed a less than 0.3% prevalence of out-of-hospital cardiac arrest 90 days after myocardial infarction, according to study data published in the Journal of the American College of Cardiology. Read more.

Quality of life not significantly improved in atrial fibrillation, symptomatic heart failure with digoxin, bisoprolol

At 6 months, quality of life in patients with permanent atrial fibrillation and symptomatic heart failure treated with digoxin was not significantly different vs. those treated with bisoprolol, researchers reported. Read more.

Tocilizumab reduces systemic inflammation in comatose out-of-hospital cardiac arrest

Tocilizumab (Actemra, Genentech), an interleukin-6 inhibitor, successfully reduced systemic inflammation and cardiac injury in resuscitated comatose patients with out-of-hospital cardiac arrest compared with placebo, according to results of the IMICA trial. Read more.